{"entity":{"id":"idea-upgrade-influenza-post-exposure-prophylaxis-versus-early-treatment-in-cancer","kind":"idea","name":"Preventive oseltamivir after flu exposure compared with a ready supply for early treatment, in people on cancer treatment","aka":[],"tldr":"When someone on cancer treatment is exposed to flu at home, guidelines offer two routes: a preventive course of oseltamivir straight away, or having the tablets ready and starting a full treatment course at the first symptom. The bodies that write the guidelines disagree on which to prefer, and neither route has been tested in people with cancer.","summary":"The positions. The German AGIHO guideline (2025) recommends post-exposure prophylaxis for immunocompromised patients with cancer, ideally within 72 hours, graded BIIt, the t meaning the evidence is transferred from other patient groups. The IDSA guideline (2018) says only that prophylaxis can be considered for severely immunocompromised people in whom vaccination is expected to work poorly (C-II), and lists educating patients and arranging early treatment as an alternative (C-III). UKHSA (2026) offers ten days of once-daily oseltamivir to at-risk contacts not adequately protected by vaccination, and allows monitoring with prompt treatment where the patient has chosen it and a pharmacy supply is arranged in advance.\n\nWhat is not known. The US oseltamivir label states that efficacy for treatment or prophylaxis has not been established in immunocompromised patients. Its household prophylaxis trial, in contacts aged 13 or older not selected for immune status, cut laboratory-confirmed clinical influenza from 12% (24 of 200) to 1% (2 of 205). The same label reports treatment-associated resistance in 27% (8 of 30) of influenza A/H1N1 infections in a treatment study of immunocompromised people. The preventive dose is once a day and the treatment dose twice a day, and UKHSA and IDSA both say to switch to treatment dosing if symptoms start during prophylaxis.\n\nNo trial comparing the two routes in people with cancer was found in any source read.","asOf":"2026-11-16","links":[{"label":"Giesen et al., Community acquired respiratory virus infections including COVID-19 in patients with cancer: 2025 updated guideline of AGIHO/DGHO (Ann Hematol 2026)","url":"https://doi.org/10.1007/s00277-026-06769-9"},{"label":"Uyeki et al., IDSA 2018 update on diagnosis, treatment, chemoprophylaxis and institutional outbreak management of seasonal influenza (Clin Infect Dis 2019)","url":"https://doi.org/10.1093/cid/ciy866"},{"label":"UKHSA, Guidance on use of antiviral agents for the treatment and prophylaxis of seasonal influenza (updated 23 October 2026)","url":"https://www.gov.uk/government/publications/influenza-treatment-and-prophylaxis-using-anti-viral-agents/guidance-on-use-of-antiviral-agents-for-the-treatment-and-prophylaxis-of-seasonal-influenza"},{"label":"TAMIFLU (oseltamivir phosphate): US prescribing information, manufacturer's label (DailyMed)","url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee3c9555-60f2-4f82-a760-11983c86e97b"}],"tags":["protocol-upgrade","upgrade:untested","evidence:insufficient"],"related":[],"cancers":[],"sections":["supportive-care"],"technologies":["allogeneic-hsct"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":["b-trial-design","b-toxicity-qol"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hypothesis":"In adults on immunosuppressive cancer treatment with a household exposure to influenza, a pre-supplied treatment course started at the first symptom leads to no more hospital admissions with influenza within 30 days than ten days of post-exposure oseltamivir, with fewer courses taken and less resistant virus.","rationale":"Exposure at home is common every winter, the two routes use the same cheap medicine in different ways, and the guideline bodies grade their advice on transferred evidence or expert opinion. The answer would settle a disagreement between AGIHO, IDSA and UKHSA.","test":"A multicentre randomised trial over two or more influenza seasons in adults on chemotherapy or within a year of a stem cell transplant with a household contact who has confirmed or strongly suspected influenza: post-exposure oseltamivir for ten days against a pre-supplied treatment course with a same-day test at first symptoms. Outcomes: laboratory-confirmed influenza, lower respiratory tract disease, admission, delay to cancer treatment, and resistance testing of every positive sample.","maturity":"speculative","actor":"research","cost":"medium","horizonYears":4},"route":"/ideas/idea-upgrade-influenza-post-exposure-prophylaxis-versus-early-treatment-in-cancer/","neighbours":{"section":[{"id":"supportive-care","kind":"section","name":"Supportive Care & Survivorship","route":"/fronts/supportive-care/"}],"technology":[{"id":"allogeneic-hsct","kind":"technology","name":"Allogeneic stem cell transplantation","route":"/technologies/allogeneic-hsct/"}],"bottleneck":[{"id":"b-toxicity-qol","kind":"bottleneck","name":"Toxicity and quality of life are undervalued","route":"/bottlenecks/b-toxicity-qol/"},{"id":"b-trial-design","kind":"bottleneck","name":"Trial design, endpoints and cost","route":"/bottlenecks/b-trial-design/"}],"protocol":[{"id":"influenza-antiviral-prophylaxis-and-early-treatment","kind":"protocol","name":"Influenza during cancer treatment: antiviral prophylaxis after exposure and early treatment","route":"/protocols/influenza-antiviral-prophylaxis-and-early-treatment/"}]}}